TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris United States
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III (AT III)
(Thrombate)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
Home
About Talecris
Therapeutic Areas
Research & Development
Donor to Patient
Media Center
Talecris Careers
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information
Media Center Overview
Press Releases
Subscribe to the Talecris Press Release RSS feed (W3C validated)
July 24, 2008
Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission
June 16, 2008
Talecris Biotherapeutics, Inc. Provides Business Update
May 22, 2008
Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation
May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
May 08, 2008
FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP
See how Talecris is being
recognized for innovation and commitment
.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2008 Talecris Biotherapeutics
